Experimental Pill Daraxonrasib Nearly Doubles Survival In Advanced Pancreatic Cancer
Daraxonrasib nearly doubled median survival to 13.2 months versus 6.7 months in a 500-patient trial and will get expedited FDA review and expanded access.
RedStateNew Cancer Drug Opens Floodgates of Hope Beyond Pancreatic Cancer
PBS NewsHourExperimental drug shows promise against deadly pancreatic cancer
ABC NewsExperimental pill promises new hope for deadly pancreatic cancer
The GuardianDaily pill can double survival time for world’s deadliest cancer, trial shows
Overview
Researchers presented ASCO trial results showing daraxonrasib nearly doubled median survival to 13.2 months versus 6.7 months in 500 previously treated metastatic pancreatic cancer patients.
The findings were published in the New England Journal of Medicine and come as the Food and Drug Administration plans expedited review and is allowing expanded access for eligible patients.
Dr. Brian Wolpin of the Dana-Farber Cancer Institute said the drug should become "a new standard of care," and outside specialists reported durable benefit and improved symptoms.
Revolution Medicines funded the study and the drug targets KRAS mutations in more than 90% of pancreatic cancers, while the American Cancer Society estimates about 67,000 new U.S. cases and over 52,000 deaths.
Researchers will test daraxonrasib earlier in disease, probe activity against KRAS subtypes, and continue tracking patients while oncologists manage a flood of special-access requests.
Analysis
Center-leaning sources frame the story as an optimistic breakthrough by foregrounding survival gains and upbeat expert reactions, using loaded descriptors (e.g., 'very large step forward'), elevating clinician and patient anecdotes, and noting FDA expedites. they downplay uncertainties — limited follow-up, side-effect nuance, cost and industry funding receive less emphasis — creating hopeful momentum.